uniQure N.V. QURE was a big mover last session, as the company saw its shares rise nearly 12% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent trend for the company-as the stock is now up 44.4% in the past one-month time frame.
The company has seen no estimate revisions over the past one month, and the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
uniQure currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.
uniQure N.V. Price and Consensus
A better-ranked stock in the Medical - Biomedical and Genetics industry is Axovant Sciences Ltd . AXON , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.